Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiated soquelitinib atopic dermatitis Phase 2 trial Completed public offering raising net proceeds of

#CRVS Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/CRVS/corvus-pharmac...

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 Corvus Pharmaceuticals (NASDAQ: CRVS) will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results. The event offers live dial-in, instant telephone access, and a webcast via investor relations. A replay will be available on Corvus' website for 90 days.

#CRVS Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

www.stocktitan.net/news/CRVS/corvus-pharmac...

Just In: ( NASDAQ: #CRVS ) CRVS Price Target Alert: $30.00. Issued by Mizuho Securities

BREAKING NEWS: ( NASDAQ: #CRVS ) CRVS Price Target Alert: $42.00. Issued by Jefferies

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an upsized underwritten public offering of 7,900,677 shares of its common stock at a price to the public of $22.15

#CRVS Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

www.stocktitan.net/news/CRVS/corvus-pharmac...

JUST IN: ( NASDAQ: #CRVS ) CRVS Price Target Alert: $32.00. Issued by Oppenheimer

Viet Nam has signed the National Action Program on CRVS for 2026-2030, a landmark commitment to a #CRVS system #CountingEveryone with @unfpa.org.

Learn more about #TheLifesavingPotentialOfDeathData and the @bloombergdotorg.bsky.social #Data4Health Initiative: https://vitalstrat.org/4b7h2rj

#CRVS shares rose to new highs after positive Phase 1 clinical trial results and strong delivery numbers

Today’s most trending tickers with positive sentiment (last 24h):

#NFLX: 54
#SPY: 18
#TSLA: 12
#AAPL: 11
#CRVS: 10
#ASTS: 9
#INTC: 8
#RIME: 7
#IBRX: 7
#SLV: 6
#META: 6
#GOLD: 6
#SPX: 5
#MU: 5
#NVDA: 5
#BTC: 5
#SNDK: 5
#LIVE: 5

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Corvus Pharmaceuticals (Nasdaq: CRVS) commenced an underwritten public offering of $150,000,000 of common stock and pre-funded warrants on January 20, 2026, with a 30-day underwriter option to purchase up to an additional $22,500,000 of common stock. Net proceeds are expected to be used for working capital and general corporate purposes, including capital expenditures and research and development for its Phase 3 T cell lymphoma program and Phase 2 trials in atopic dermatitis, hidradenitis suppurativa and asthma. Jefferies and Goldman Sachs are lead managers. The offering is subject to market conditions and will be made by prospectus supplement under an S-3 shelf declared effective August 15, 2024.

#CRVS Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/CRVS/corvus-pharmac...

Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis Corvus Pharmaceuticals (NASDAQ: CRVS) reported positive Phase 1 cohort 4 results for oral soquelitinib in moderate-to-severe atopic dermatitis. At Day 56 (n=12 soquelitinib, n=10 evaluable placebo) soquelitinib achieved EASI 75 in 75%, EASI 90 in 25% and IGA 0/1 in 33%, with mean EASI reduction of 72% vs 40% placebo and a statistically significant separation (p=0.035). Safety showed adverse events in 41.7% of treated patients vs 50% placebo; all events were Grade 1-2 with no serious adverse events. Biomarkers showed reductions in IL-4, IL-5, IL-17 and increased Treg cells. Corvus plans a ~200-patient Phase 2 trial in Q1 2026 with multiple dose arms and 12-week treatment.

#CRVS Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

www.stocktitan.net/news/CRVS/corvus-pharmac...

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis Corvus Pharmaceuticals (NASDAQ: CRVS) will report results from cohort 4 of its randomized, blinded, placebo-controlled Phase 1 trial of soquelitinib in moderate to severe atopic dermatitis on Tuesday, January 20, 2026 at 8:00 am ET (5:00 am PT).The company will host a conference call and live webcast with presentation slides; domestic dial-in is 1-800-717-1738 and international is 1-646-307-1865. The live webcast and slides are available via Corvus investor relations, and a replay will be available on the website for 60 days.

#CRVS Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

www.stocktitan.net/news/CRVS/corvus-pharmac...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#GTES, #TMC, #LKQ, #CVNA, #CRVS

#OptionFlow #OptionsTrading #Trading

Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 1 trial in atopic dermatitis and potential expansion

#CRVS Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial

www.stocktitan.net/news/CRVS/corvus-pharmac...

This week, Vital attended an event on improved #CRVS in Francophone Africa organized by @who.int & Organisation Internationale de la Francophonie (OIF). In addition, Bloomberg Philanthropies #Data4Health country representatives from Cambodia, Rwanda, Cameroon and Senegal shared their stories.

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results Corvus Pharmaceuticals (NASDAQ: CRVS) provided a business update and reported Q3 2025 results on Nov 4, 2025. Key clinical milestones include completed enrollment in the soquelitinib atopic dermatitis Phase 1 extension cohort 4 with data anticipated in Jan 2026, a Phase 2 atopic dermatitis trial on track to start in early Q1 2026 (≈200 patients), and an ongoing registrational Phase 3 in relapsed/refractory PTCL (target ≈150 patients) with final Phase 1/1b data to be presented orally at ASH Dec 2025.Financials: cash, cash equivalents and marketable securities of $65.7M as of Sept 30, 2025, expected to fund operations into Q4 2026. R&D expense for Q3 2025 was $8.5M vs $5.2M year-ago; net loss was $10.2M for the quarter.

#CRVS Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/CRVS/corvus-pharmac...

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025 Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast

#CRVS Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

www.stocktitan.net/news/CRVS/corvus-pharmac...

🌍 On #CRVS Day, #UNICEF #Evaluation highlights support to 90+ countries to boost birth registration. Digital tools, legal reforms & community outreach are key. Let’s ensure every child is counted & protected. #EveryChildCounts #LegalIdentityForAll 🔗 tinyurl.com/UNICEF-CRVS 👈

On #CivilRegistrationDay, we spotlight #UNICEF WCARO’s KRC#7 #evaluation: 6 in 10 kids under 5 still lack birth registration. Digital #CRVS, health system integration & community outreach are key to change. Every child deserves an identity. #EveryChildCounts 🔗Read: www.unicef.org/evaluation/r... 👈

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results Corvus Pharmaceuticals (NASDAQ:CRVS) reported significant progress in its clinical trials and financial results for Q2 2025. The company's lead drug candidate soquelitinib showed promising results in Phase 1 trials for atopic dermatitis, with cohort 3 achieving a 64.8% mean EASI reduction compared to 34.4% for placebo. The company is advancing multiple clinical programs, including a Phase 3 trial for peripheral T cell lymphoma (PTCL) and collaboration with NIAID for ALPS treatment.Financially, Corvus strengthened its position with warrant exercises providing $35.7 million in proceeds during Q2, ending the quarter with $74.4 million in cash. The company expects its cash runway to extend into Q4 2026. R&D expenses increased to $7.9 million, up from $4.1 million in Q2 2024, with a net loss of $8.0 million.

#CRVS Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/CRVS/corvus-pharmac...

Clinical-Stage Biotech Corvus Pharmaceuticals Sets Q2 2025 Earnings Release: Key Updates Coming August 7 Clinical-stage biotech Corvus Pharmaceuticals announces Q2 earnings webcast with business updates. Join live presentation August 7 at 4:30 PM ET. Get details here.

#CRVS Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025

www.stocktitan.net/news/CRVS/corvus-pharmac...

Our #Data4Health team joined partners at the Third Ministerial Conference on Civil Registration and Vital Statistics in Asia and the Pacific to discuss strengthening #CRVS to #GetEveryoneInThePicture.

Here's a recap 👇

This work contributes to building more inclusive, responsive, and evidence-driven health systems—today and for the long term. #CRVS #SampleRegistration #GlobalHealth #PublicHealthData /4

The #symposium will bring together government representatives, #gender experts, international organizations, civil society, and academic institutions to explore the intersections between gender and #CRVS systems and develop strategies to promote gender-responsive CRVS systems globally.

At the Ministerial Conference on #CRVS, IOM delivered a statement, underscoring barriers migrants face in accessing civil registration, legal identity & regular pathways, and reaffirming our resolution to build inclusive, migrant-responsive systems that leave no one behind to achieve the 2030 Goals

Millions remain invisible – but Asia-Pacific leaders pledge change by 2030 More than a decade after Asian and Pacific nations launched a campaign to ensure every life is counted, millions across the region still remain “invisible” – born, living, and dying without formal recognition.

Millions remain invisible – but Asia-Pacific leaders pledge change by 2030

#EveryoneCounts #CivilRegistrationAndVitalStatistics #CRVS

Honored to moderate a vibrant discussion by panels from 🇫🇯 🇰🇬🇳🇵🇱🇰🇹🇭 at 🇺🇳UN ESCAP Ministerial Conference on Civil Registration and Vital Statistics.🙏🏻
Our dialogue reconfirmed the criticality of inclusive #CRVS systems that ensure #legalidentity for all.
#2030Agenda
#SDGs
#LNOB

How do we protect children’s legal identity amid climate crises?
Join @UNICEF at #3MCCRVS for a side event on building climate-resilient birth registration systems, with insights from Nepal, PNG, and Philippines.
🗓️ 26/06/25 | 12:45 BKK | Rm A / Online
#CRVS #LegalIdentity #ClimateResilience #UNICEF

New Drug Breakthrough: Corvus's Soquelitinib Shows Promising Results for Systemic Sclerosis Treatment at EULAR 2025 Top-ranked EULAR study reveals soquelitinib's potential to prevent lung damage in systemic sclerosis patients. See groundbreaking preclinical results.

#CRVS Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress

www.stocktitan.net/news/CRVS/corvus-pharmac...

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis Corvus Pharmaceuticals (NASDAQ: CRVS) reported positive Phase 1 clinical trial data for soquelitinib in treating moderate to severe atopic dermatitis. Cohort 3 (200mg twice daily) showed superior results compared to cohorts 1-2, with a 64.8% mean EASI score reduction vs 54.6% for cohorts 1-2 and 34.4% for placebo at day 28. The drug demonstrated statistically significant improvement (p=0.036) and earlier response onset, with itch reduction observed as early as day 8. Safety profile was favorable with no dose-limiting toxicities. Notably, 50% of evaluable Cohort 3 patients achieved clinically meaningful itch reduction. The company has initiated an extension study with an 8-week treatment period at the Cohort 3 dose level to explore longer-duration benefits.

#CRVS Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

www.stocktitan.net/news/CRVS/corvus-pharmac...